In Devices, Abbott Bulks Up: An Interview with Rick Gonzalez
Abbott's recent acquisition of Guidant's vascular business was an important boost in the company's efforts to build a major cardiovascular franchise, but it was only the latest in a concerted effort to create a broad-based device business. One of the key architects of Abbott's growth in the field is COO Rick Gonzalez. In the an interview, Gonzalez looks back on a career that has taken him to the top at Abbott and reflects on what the Guidant deal and other important moves will mean to Abbott's device operations.
by David Cassak
Wouldn’t it be interesting if the ultimate winner in the sweepstakes for Guidant Corp. that has played out over...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
MoonLake Immunotherapeutics is racing ahead in the biotech space with its innovative nanobody SLK and a transformative $500m non-dilutive financing deal. In this episode, its CEO and CFO discuss the company’s rapid clinical progress, financial strategy and ambitions to reshape inflammatory disease.
Aneesh Karatt-Vellatt is leading the charge to redefine how ion channels and G protein-coupled receptors (GPCRs) are targeted with antibody therapies, one of the most notoriously challenging classes of drug targets.
In the latest podcast interview, Phil L'Huillier, CEO of Scancell, discussed the company's work in cancer vaccine development, and its selection as the first British biotech to be a part of the NHS Cancer Vaccine Launch Pad.
In Vivo spoke with Edward Ahn, CEO of Medipost, a Korean company that has developed stem cell therapies from cord blood, on how they are working across regulatory markets to provide a novel treatment for degenerative diseases.
Aneesh Karatt-Vellatt is leading the charge to redefine how ion channels and G protein-coupled receptors (GPCRs) are targeted with antibody therapies, one of the most notoriously challenging classes of drug targets.
In the latest podcast interview, Phil L'Huillier, CEO of Scancell, discussed the company's work in cancer vaccine development, and its selection as the first British biotech to be a part of the NHS Cancer Vaccine Launch Pad.
New report by global law firm Taylor Wessing and Bayes Business School forecasts a steadily increasing volume of major life sciences M&A in the coming five years, but highlights concerns over cybersecurity and unrealistic valuations. Taylor Wessing partner Andrew Edge spoke to In Vivo.